A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2004-04-01

Target enrollment:

Participant gender:

Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis

Phase 3

Astellas Pharma Inc

Biogen

Alefacept